Filing search / Lineage Cell Therapeutics, Inc. / "Safety" / Page 2

8-K

EX-99.1

l6lcmhsg9

12 May 22

LINEAGE CELL THERAPEUTICS REPORTs FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

4:10pm

8-K

2jggqqz

11 May 22

Regulation FD Disclosure

7:54pm

8-K

EX-99.1

8qp61jx3hcg8fko4fzt

11 May 22

Regulation FD Disclosure

7:54pm

8-K

EX-99.1

o7k5wl4c giyx

10 Mar 22

LINEAGE CELL THERAPEUTICS REPORTs FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

4:10pm

8-K

u407iw454aoed

20 Dec 21

Entry into a Material Definitive Agreement

6:06am

8-K

EX-99.1

nkkhi59yts

20 Dec 21

Entry into a Material Definitive Agreement

6:06am

8-K

EX-99.1

uqlk7 ld574

13 Dec 21

Regulation FD Disclosure

4:10pm

8-K

EX-99.1

fu7rfv56 lre872v

10 Nov 21

LINEAGE REPORTs THIRD QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS

4:10pm

8-K

EX-99.1

m3r64

30 Sep 21

Regulation FD Disclosure

5:29pm

8-K

EX-99.1

syydx

12 Aug 21

LINEAGE REPORTs SECOND QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS ADDITIONAL PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS

4:10pm

8-K

EX-99.1

gjlmbu

1 Jun 21

Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration In Dry Amd Patients Treated with Opregen® Rpe Cells

7:00am

8-K

bjpxombta821

1 Jun 21

Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration In Dry Amd Patients Treated with Opregen® Rpe Cells

7:00am